Xinran Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xinran Zhang has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Feng Han
Department of Hepatic Biliary Pancreatic Surgery, Cancer Hospital Affiliated to Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan, China
35 shared publications - Hao Zhuang
Department of Hepatobiliopancreatic Surgery The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital Zhengzhou China
35 shared publications - Jianing Huang
Department of Pathogen Biology and Department of Genetics, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China
35 shared publications - Li Sun
Department of Gynaecology and Obstetrics, The Second Hospital of Tianjin Medical University, Tianjin 300211, China
35 shared publications - Mengya Guo
Department of Pathogen Biology and Department of Genetics, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China
35 shared publications - Minghe Li
Department of Pathogen Biology and Department of Genetics, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China
35 shared publications
Latest Publications
- 15 June 2026
- Published by BMJ in BMJ Evidence-Based Medicine
Safety of proton pump inhibitors: an overview of systematic reviews and meta-analyses
Background: Proton pump inhibitors (PPIs) have been widely used for over 35 years. However, in recent decades, numerous adverse drug reactions (ADRs) have been reported, with evidence often inconsistent and heterogeneous across studies. Objective: To conduct an overview of systematic reviews/meta-analyses (SR/MAs) to provide a contemporary review of the evidence for the safety of PPIs in patients using them for treating or prophylaxis, to summarise the outcome data, assess the methodological quality and rate the certainty of the evidence and to provide references for clinical decision-making and the subsequent formulation of evidence. Methods: We conducted an overview of reviews following the Preferred Reporting Items for Overviews of Reviews guidelines. We identified SR/MAs regarding PPI safety through a search of multiple databases, including the China National Knowledge Infrastructure, Chinese Science and Technology Journal Database and Wanfang Database (WanFang) on 6 December 2025 as well as Embase, PubMed and the Cochrane Library database on 7 December 2025. The participants were human populations who had been administered PPIs; the intervention groups used PPI-based regimens and the control group received different PPI regimens, no-PPIs, H2-receptor antagonists (H2RAs), potassium-competitive acid blockers (P-CAB) or placebo; the outcomes mainly included the specific ADRs associated with PPI use. We used the A Measurement Tool to Assess Systematic Reviews-2 (AMSTAR-2) tool to assess the methodological quality of the included SR/MAs and employed the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework to evaluate the quality of evidence for the reported outcomes. The focus of the data presentation was descriptive, featuring detailed tabular presentations of characteristics and results at both the review level and the primary studies level. Main results: A total of 940 studies were retrieved from various databases according to the search strategies. After eliminating duplicates and the screening process, 36 SR/MAs were finally included. Overall, there was a slight overlap (corrected covered area, CCA of 0.91%) in 483 primary studies included in the 36 SR/MAs. AMSTAR-2 evaluation results showed that 34 SR/MAs were of low quality, and the other two were of critically low quality. The GRADE evaluation results indicated that the certainty of evidence for all outcomes was low or very low . The use of PPIs might be associated with an increased risk of acute kidney injury (AKI) (relative risk (RR) 1.75, 95% CI 1.40 to 2.19), chronic kidney disease (CKD) (RR 1.35, 95% CI 1.15 to 1.56), gastric cancers (GC) (RR 1.67, 95% CI 1.39 to 2.00) and community-acquired pneumonia (CAP) (OR 1.37, 95% CI 1.22 to 1.53). PPI therapy was associated with a higher recurrence rate of Clostridioides difficile infection (CDI) (24% vs 18%) and might increase CDI risk in renal transplant recipients (RR 2.33, 95% CI 1.07 to 5.07). The use of PPIs might heighten the risk of fractures in young patients (aged low or very low certainty evidence that limits definitive causal conclusions. Clinicians and pharmacists may consider greater vigilance with PPI use, and these ADRs may not require de-escalation but de-implementation when inadequate (eg, long-term use or special group use). Future research should focus on high-quality prospective studies and investigate underlying mechanisms to better establish causality and quantify risks. PROSPERO registration number: CRD420251059575.
- 15 June 2026
- Published by BMJ in BMJ Evidence-Based Medicine
Safety of proton pump inhibitors: an overview of systematic reviews and meta-analyses
Background: Proton pump inhibitors (PPIs) have been widely used for over 35 years. However, in recent decades, numerous adverse drug reactions (ADRs) have been reported, with evidence often inconsistent and heterogeneous across studies. Objective: To conduct an overview of systematic reviews/meta-analyses (SR/MAs) to provide a contemporary review of the evidence for the safety of PPIs in patients using them for treating or prophylaxis, to summarise the outcome data, assess the methodological quality and rate the certainty of the evidence and to provide references for clinical decision-making and the subsequent formulation of evidence. Methods: We conducted an overview of reviews following the Preferred Reporting Items for Overviews of Reviews guidelines. We identified SR/MAs regarding PPI safety through a search of multiple databases, including the China National Knowledge Infrastructure, Chinese Science and Technology Journal Database and Wanfang Database (WanFang) on 6 December 2025 as well as Embase, PubMed and the Cochrane Library database on 7 December 2025. The participants were human populations who had been administered PPIs; the intervention groups used PPI-based regimens and the control group received different PPI regimens, no-PPIs, H2-receptor antagonists (H2RAs), potassium-competitive acid blockers (P-CAB) or placebo; the outcomes mainly included the specific ADRs associated with PPI use. We used the A Measurement Tool to Assess Systematic Reviews-2 (AMSTAR-2) tool to assess the methodological quality of the included SR/MAs and employed the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework to evaluate the quality of evidence for the reported outcomes. The focus of the data presentation was descriptive, featuring detailed tabular presentations of characteristics and results at both the review level and the primary studies level. Main results: A total of 940 studies were retrieved from various databases according to the search strategies. After eliminating duplicates and the screening process, 36 SR/MAs were finally included. Overall, there was a slight overlap (corrected covered area, CCA of 0.91%) in 483 primary studies included in the 36 SR/MAs. AMSTAR-2 evaluation results showed that 34 SR/MAs were of low quality, and the other two were of critically low quality. The GRADE evaluation results indicated that the certainty of evidence for all outcomes was low or very low . The use of PPIs might be associated with an increased risk of acute kidney injury (AKI) (relative risk (RR) 1.75, 95% CI 1.40 to 2.19), chronic kidney disease (CKD) (RR 1.35, 95% CI 1.15 to 1.56), gastric cancers (GC) (RR 1.67, 95% CI 1.39 to 2.00) and community-acquired pneumonia (CAP) (OR 1.37, 95% CI 1.22 to 1.53). PPI therapy was associated with a higher recurrence rate of Clostridioides difficile infection (CDI) (24% vs 18%) and might increase CDI risk in renal transplant recipients (RR 2.33, 95% CI 1.07 to 5.07). The use of PPIs might heighten the risk of fractures in young patients (aged low or very low certainty evidence that limits definitive causal conclusions. Clinicians and pharmacists may consider greater vigilance with PPI use, and these ADRs may not require de-escalation but de-implementation when inadequate (eg, long-term use or special group use). Future research should focus on high-quality prospective studies and investigate underlying mechanisms to better establish causality and quantify risks. PROSPERO registration number: CRD420251059575.
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from LINC00869 Promotes Hepatocellular Carcinoma Metastasis via Protrusion Formation
Heatmap of enriched lncRNAs binding to WASp and Arp2 protein determined by RIP-seq.
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from LINC00869 Promotes Hepatocellular Carcinoma Metastasis via Protrusion Formation
Heatmap of enriched lncRNAs binding to WASp and Arp2 protein determined by RIP-seq.
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from LINC00869 Promotes Hepatocellular Carcinoma Metastasis via Protrusion Formation
LINC00869 promotes cell migration, invasion and proliferation in HCC cells.
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from LINC00869 Promotes Hepatocellular Carcinoma Metastasis via Protrusion Formation
LINC00869 promotes cell migration, invasion and proliferation in HCC cells.
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from LINC00869 Promotes Hepatocellular Carcinoma Metastasis via Protrusion Formation
Summary of the sequencing coverage and quality statistics of the RIP-Seq analysis.
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from LINC00869 Promotes Hepatocellular Carcinoma Metastasis via Protrusion Formation
Summary of the sequencing coverage and quality statistics of the RIP-Seq analysis.
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from LINC00869 Promotes Hepatocellular Carcinoma Metastasis via Protrusion Formation
Clinicopathological information of HCC specimens for RNA-ISH.
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from LINC00869 Promotes Hepatocellular Carcinoma Metastasis via Protrusion Formation
Clinicopathological information of HCC specimens for RNA-ISH.
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from LINC00869 Promotes Hepatocellular Carcinoma Metastasis via Protrusion Formation
LINC00869 promotes actin polymerization and protrusion formation.
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from LINC00869 Promotes Hepatocellular Carcinoma Metastasis via Protrusion Formation
LINC00869 promotes actin polymerization and protrusion formation.
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from LINC00869 Promotes Hepatocellular Carcinoma Metastasis via Protrusion Formation
Sequences of the genes coding shRNA for LINC00869 knockdown experiments.
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from LINC00869 Promotes Hepatocellular Carcinoma Metastasis via Protrusion Formation
Sequences of the genes coding shRNA for LINC00869 knockdown experiments.
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from LINC00869 Promotes Hepatocellular Carcinoma Metastasis via Protrusion Formation
Sequences of the DNA primers for RT-qPCR and in vitro transcription, and the sequences of LINC00869 probes.
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from LINC00869 Promotes Hepatocellular Carcinoma Metastasis via Protrusion Formation
Sequences of the DNA primers for RT-qPCR and in vitro transcription, and the sequences of LINC00869 probes.
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from LINC00869 Promotes Hepatocellular Carcinoma Metastasis via Protrusion Formation
LINC00869 promotes cell migration, invasion and proliferation in HCC cells.
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from LINC00869 Promotes Hepatocellular Carcinoma Metastasis via Protrusion Formation
LINC00869 promotes cell migration, invasion and proliferation in HCC cells.
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from LINC00869 Promotes Hepatocellular Carcinoma Metastasis via Protrusion Formation
Clinicopathological information of the HCC tissue samples for RT-qPCR.
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from LINC00869 Promotes Hepatocellular Carcinoma Metastasis via Protrusion Formation
Clinicopathological information of the HCC tissue samples for RT-qPCR.